Measles vaccine
Phase 3Vaccine
GSKMeasles vaccine is one of 32 biologic programs targeting Vaccination. It is currently in Phase 3.
3
Indications
15
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Randomized Controlled Trial
#DrugCompanyPhaseTrials
1Carafate
AbbVieApproved
Xylocaine
MMEDRx USA, Inc.
Phase 3
Antibiotic
PfizerPhase 3
Aldactone
PfizerPhase 2
Zofran
NovartisPhase 2
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
Bone Marrow Aspirate Concentrate
MMassachusetts General Hospital
Phase 3
Takecab
PPhathom Pharmaceuticals, Inc.
Phase 2
Epidiolex
Jazz PharmaceuticalsPhase 1
Measles vaccine
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vaccination2 trials
Measles Vaccine2 trials
8 more indications
Mortality1 trial
Japanese encephalitis1 trial
Rotavirus Vaccine1 trial
Pediatric1 trial
Randomized Controlled Trial1 trial
Randomized Controlled Trial of Measles Vaccination Schedule
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT03170765·120 enrolled
Hepatitis B1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Measles vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]